Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17372613 | 0.82 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL546675 | 0.80 | — | — | |
| SCHEMBL17372419 | 0.79 | CYP1A2 (0.30) | CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17372415 | 0.79 | CYP1A2 (0.30) | CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL28960555 | 0.78 | MEN1 (0.38) | CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL29278769 | 0.71 | SPHK1 (0.32) | CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6765504 | 0.71 | KDM4E (0.48) | CYP1A2CYP2D6CYP2C19ADORA3ADORA2A | |
| SCHEMBL25244196 | 0.70 | CYP1A2 (0.31) | CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL28960558 | 0.69 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2D6CYP2C19ADORA3 | |
| SCHEMBL29124870 | 0.68 | SYK (0.37) | CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238212-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240218399-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SUZHOU ABOGEN BIOSCIENCES CO LTD (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024140624-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024134511-A2 | LIPID NANOPARTICLE COMPOSITION | Seqirus Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024134512-A1 | LIPID NANOPARTICLE COMPOSITION | Seqirus Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240189408-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. | 2024-06-13 | — | — | US | disclosed |
| EP-3917503-B1 | METHODS OF PREPARING LIPID NANOPARTICLES | MODERNATX INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11969506-B2 | Lipid nanoparticle formulation | MODERNATX, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| WO-2024084397-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | PFIZER INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240131150-A1 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | SUZHOU ABOGEN BIOSCIENCES CO LTD (CN) | 2024-04-25 | — | — | US | disclosed |
| WO-2017066793-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066781-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066797-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066782-A1 | HYDROPHOBIC MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066789-A1 | MRNA CAP ANALOGS WITH MODIFIED SUGAR | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017049245-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049286-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049275-A2 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2015196118-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11969506-B2 | Lipid nanoparticle formulation | TTPA, SREBF1, SREBF2 | CYP1A2 2248/4885CYP3A4 2259/4885CYP2D6 1756/4885 |
| US-20240238212-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | CYP1A2 4101/4885CYP3A4 4049/4885CYP2D6 3915/4885 |
| US-20240189408-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | MT-CO2, CYB5R3, COX5A | CYP1A2 400/4885CYP3A4 425/4885CYP2D6 901/4885 |
| US-20240131150-A1 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | SARS1, POLRMT, SARNP | CYP1A2 4592/4885CYP3A4 4664/4885CYP2D6 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.